This week we open with a critical take on our current system of disseminating scientific research, specifically focusing on the prevalence of -- and dependence on -- medical writers. In the second half of the episode, we interview Dr. Allen Pannell of the Haslam College of Business at the University of Tennessee on using a Frequentist approach vs a Bayesian approach in the context of a single clinical trial. 

Frequentist vs Bayesian: doi.org/10.1136/bmjopen-2018-024256
Dr. Pannell's breast cancer support group: https://www.breastconnect.org/
Dr. Pannell's research project: http://tinyurl.com/peerErPrHer2

Back us on Patreon! www.patreon.com/plenarysession

1.67 MONALEESA-7 and the Cost of Cancer Drugs with Dr. Stacie Dusetzina

Dr Prasad currently serves as the Director of the Center for Biologics Evaluation and Resesarch (CBER) at the US FDA. The audio on this platform were posted before my FDA employment and do not necessarily represent the views of the FDA or the United States. This site will be inactive during my federal service.

A podcast on medicine, oncology, & health policy. 
Host: Vinay Prasad, MD MPH from University of California San Francisco.
Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com